Tirzepatide is a dual GIP/GLP-1 receptor agonist delivering synergistic effects on appetite, metabolism, and body composition. Physician-reviewed. Prescription required.
Tirzepatide is a novel incretin-based peptide drug that works through dual activation of the GLP-1 (glucagon-like peptide-1) receptor and GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual agonism produces synergistic effects on glucose metabolism, appetite regulation, gastric emptying, and energy balance — delivering outcomes that exceed either pathway alone.
Unlike GLP-1-only agents, Tirzepatide’s GIP receptor activation provides additional metabolic benefits including improved insulin sensitivity, enhanced lipid metabolism, and increased energy expenditure. Clinical data consistently shows superior weight loss outcomes compared to GLP-1 monotherapy. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Dual GLP-1 + GIP receptor agonism | Enhanced incretin signaling |
| Glucose-dependent insulin secretion | Better glycemic control |
| Glucagon suppression | Reduced hepatic glucose output |
| Slowed gastric emptying | Lower postprandial glucose |
| Central appetite suppression | Reduced caloric intake |
| β-cell protection | Sustained insulin production |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Tirzepatide protocol candidates in clinical practice:
Weight Management
Individuals with BMI ≥27 with comorbidities or ≥30 seeking physician-supervised GLP-1/GIP dual therapy.
Type 2 Diabetes
Individuals with T2D seeking dual incretin-based glycemic control under physician supervision.
Metabolic Optimization
Individuals pursuing physician-reviewed metabolic health optimization as part of a comprehensive longevity protocol.
Prior GLP-1 Plateau
Individuals who have plateaued on semaglutide and may benefit from dual GLP-1/GIP receptor agonism.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
2.5–15 mg/week (physician-titrated)
Administration
Subcutaneous injection (weekly)
Duration
Ongoing with periodic reassessment
Frequency
Once weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.